R-E Klingenberg1, S Esser2, N H Brockmeyer1,3, C Michalik3,4, A Skaletz-Rorowski1,3, A Potthoff5. 1. Interdisziplinäre Immunologische Ambulanz, Zentrum für Sexuelle Gesundheit und Medizin, WIR - Walk In Ruhr, Klinik für Dermatologie, Venerologie und Allergologie, Ruhr-Universität Bochum, Große Beck Str. 12, 44787, Bochum, Deutschland. 2. Klinik für Dermatologie, Universitätsklinikum Essen, Essen, Deutschland. 3. Kompetenznetz HIV/AIDS, Bochum, Deutschland. 4. Zentrum für klinische Studien, Köln, Deutschland. 5. Interdisziplinäre Immunologische Ambulanz, Zentrum für Sexuelle Gesundheit und Medizin, WIR - Walk In Ruhr, Klinik für Dermatologie, Venerologie und Allergologie, Ruhr-Universität Bochum, Große Beck Str. 12, 44787, Bochum, Deutschland. a.potthoff@klinikum-bochum.de.
Abstract
BACKGROUND: Kaposi's sarcoma (KS) represents the most common AIDS-defining neoplasm. Only very few studies regarding the course and treatment of human immunodeficiency virus (HIV)-associated KS have been carried out in Germany. OBJECTIVE: In this study the course of HIV-associated KS was observed in patients from the cohort database of the competence network for HIV/AIDS. MATERIAL AND METHODS: Data from HIV-associated KS patients from 9 German core centers from 1987 to 2011 were retrospectively collected. Kaplan-Meier curves for the recurrence and survival probability were calculated. RESULTS: In 222 patients KS was diagnosed at a median age of 38.5 ± 10.1 years. Men were almost exclusively affected (97.7%). The HIV viral load at the time of diagnosis was in 7.4% <50 copies/ml. Of the patients 55.5% developed KS with a CD4 cell count of <200 cells/μl and 9.5% with >500 cells/μl. In 68 patients KS therapy consisted exclusively of the optimization or initiation of antiretroviral therapy (ART). In addition, 71 patients were treated with pegylated liposomal doxorubicin. During the median follow-up period of 8.9 ± 4.9 years, 80.2% of the patients were free of KS recurrence. Survival rates after 5 and 10 years were 96.8% and 91.3%, respectively. CONCLUSION: Even with a good immune status HIV-associated KS occurred. An effective ART was the most important mainstay of therapy. With appropriate therapy, HIV-positive patients with KS showed a good survival rate.
BACKGROUND:Kaposi's sarcoma (KS) represents the most common AIDS-defining neoplasm. Only very few studies regarding the course and treatment of human immunodeficiency virus (HIV)-associated KS have been carried out in Germany. OBJECTIVE: In this study the course of HIV-associated KS was observed in patients from the cohort database of the competence network for HIV/AIDS. MATERIAL AND METHODS: Data from HIV-associated KS patients from 9 German core centers from 1987 to 2011 were retrospectively collected. Kaplan-Meier curves for the recurrence and survival probability were calculated. RESULTS: In 222 patients KS was diagnosed at a median age of 38.5 ± 10.1 years. Men were almost exclusively affected (97.7%). The HIV viral load at the time of diagnosis was in 7.4% <50 copies/ml. Of the patients 55.5% developed KS with a CD4 cell count of <200 cells/μl and 9.5% with >500 cells/μl. In 68 patients KS therapy consisted exclusively of the optimization or initiation of antiretroviral therapy (ART). In addition, 71 patients were treated with pegylated liposomal doxorubicin. During the median follow-up period of 8.9 ± 4.9 years, 80.2% of the patients were free of KS recurrence. Survival rates after 5 and 10 years were 96.8% and 91.3%, respectively. CONCLUSION: Even with a good immune status HIV-associated KS occurred. An effective ART was the most important mainstay of therapy. With appropriate therapy, HIV-positivepatients with KS showed a good survival rate.
Entities:
Keywords:
Antiretroviral therapy; CD4+ cell counts; HIV infections; Recurrence; Survival
Authors: Alexander Kreuter; Heinrich Rasokat; Mariam Klouche; Stefan Esser; Armin Bader; Thilo Gambichler; Peter Altmeyer; Norbert H Brockmeyer Journal: Cancer Invest Date: 2005 Impact factor: 2.176
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: L Martín-Carbonero; R Palacios; E Valencia; P Saballs; G Sirera; I Santos; F Baldobí; M Alegre; A Goyenechea; J Pedreira; J González del Castillo; J Martínez-Lacasa; A Ocampo; M Alsina; J Santos; D Podzamczer; J González-Lahoz Journal: Clin Infect Dis Date: 2008-08-01 Impact factor: 9.079
Authors: Mark Bower; Alessia Dalla Pria; Chris Coyle; Eileen Andrews; Victoria Tittle; Sharanjit Dhoot; Mark Nelson Journal: J Clin Oncol Date: 2013-12-30 Impact factor: 44.544
Authors: K Jansen; C Michalik; M Hahn; S Dupke; S Esser; H Jaeger; S Köppe; A Moll; A Plettenberg; R E Schmidt; A Skaletz-Rorowski; N H Brockmeyer Journal: Eur J Med Res Date: 2009-08-12 Impact factor: 2.175
Authors: S Franceschi; L Dal Maso; M Rickenbach; J Polesel; B Hirschel; M Cavassini; A Bordoni; L Elzi; S Ess; G Jundt; N Mueller; G M Clifford Journal: Br J Cancer Date: 2008-07-29 Impact factor: 7.640
Authors: I Poizot-Martin; V Obry-Roguet; C Duvivier; C Lions; T Huleux; C Jacomet; T Ferry; A Cheret; C Allavena; F Bani-Sadr; R Palich; A Cabié; A Fresard; P Pugliese; P Delobel; I Lamaury; L Hustache-Mathieu; S Brégigeon; A Makinson; D Rey Journal: J Eur Acad Dermatol Venereol Date: 2020-04-30 Impact factor: 6.166